PET/CT imaging and dosimetry as predictive factors for treatment response of the 177Lu-DOTA-TATE therapy - DOTADOSE

niversitätsklinikum Freiburg, Abteilung Nuklearmedizin0 个研究点目标入组 12 人开始时间: 2012年9月20日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•indication for 177Lu-DOTATATE therapy:
•- well differenciated, metastasized neuroendocrine tumors or carcinoma, which overexpress somatostatin receptors subtyp 2 (positive pretherapeutic 68Ga-DOTA-TATE PET/CT) and which are not able to treat curative,
•- meningiomas, which overexpress somatostatin receptors subtyp 2 and which are not able to treat with an alternative treatment.
•pro DOTATATE therapy:
•- progress of tumor, firt line, second line therapy,
•- metastasis, not local restricted to the liver,
•- significant overexpression of somatostatin receptor subtyp 2,
•- normal kidney function.
•- able and willing to give informed consent

•- renal insufficiency, creatinine >1.5 mg/dl and/or GFR <60 ml/min, fixed disease of the efferent urinary tract
•- myelosupression: thrombocytes <90tds/mycroliter, hemoglobin <8.0 g/dl, leucocytes <2.5 tds/mycroliter
•- Karnofsky index <60%
•- somatostatin receptor imaging: tumor-uptake < liver-uptake
•- pregnancy
•- relative contra-indication: proliferation index >20%

发起方

niversitätsklinikum Freiburg, Abteilung Nuklearmedizin